# Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer

Source: https://onco.cc/trials/nct06250972/  
OnCo record `nct06250972` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in pancreatic cancer, run by Fudan University, now recruiting.

## Summary

Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer is a phase 3, randomised interventional study registered as NCT06250972 by Fudan University, with a registry enrolment figure of 210 participants, started 2024-05-15 and due to reach its primary completion in 2027-05-01. Interventions recorded: Gemcitabine, Nab-paclitaxel, Irinotecan; Intensity-Modulated Radiation Therapy (IMRT). Conditions listed: Pancreatic Adenocarcinoma. Primary outcome: progression-free survival, PFS. Pancreatic eligibility wording from the registry: "* Histologically or cytologically confirmed advanced pancreas adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: PTCA199-11
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06250972
- Phase: 3
- Setting: Radiotherapy Plus Chemotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer Who Are Not Refractory to Chemotherapy
- Sponsor: Fudan University
- Enrolled: 210

## Sources

- ClinicalTrials.gov NCT06250972: https://clinicaltrials.gov/study/NCT06250972

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06250972.json